Level Nine

Executive Summary

Level Nine is a Berlin-based biotechnology company leveraging artificial intelligence and machine learning to optimize drug delivery and formulation. Founded in 2020, the company focuses on designing smarter drug carriers and release mechanisms to enhance therapeutic efficacy, safety, and patient compliance. By applying advanced computational methods to formulation science, Level Nine aims to address key challenges in drug development, such as poor bioavailability and non-compliance, across a range of therapeutic areas. The platform is preclinical and aims to partner with pharmaceutical companies to improve both existing and new drugs. Despite its innovative approach, Level Nine is at an early stage with no disclosed funding or partnerships. The drug delivery space is competitive, and the company must demonstrate tangible preclinical data and secure strategic collaborations to validate its platform. Success will depend on its ability to attract investment, build a strong IP portfolio, and achieve proof-of-concept in animal models. If successful, Level Nine could become a key enabler for more effective and patient-friendly therapies.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Partnership with Major Pharma for Formulation Optimization50% success
• Q1 2027Preclinical Proof-of-Concept Data Release60% success